Compound libraries
Products
EBC main page
Search
Dyes
Impurities
Chemical probes
Contacts us
Pfizer reference compounds
Services
© 2026 Copyright Enamine
Back
Product details:
CAS
129453-61-8
Purity
95%
Fulvestrant is a drug treatment of hormone receptor (HR)-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor.
Properties
Name
Fulvestrant
Smiles
C[C@@]12CC[C@H]3[C@H]([C@@H]2CC[C@@H]1O)[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC=4C=C(O)C=CC34
Targets
Please log in to see this information
SDS
ICI 182,780 | faslodex | fulvestrant
No data available
The compound has purity validated by NMR and/or LCMS methods.
1 mg
$68
2 mg
$72
5 mg
$80
10 mg
$103
15 mg
$118
20 mg
$132
25 mg
$144
30 mg
$152
35 mg
$167
40 mg
$186
45 mg
$198
50 mg
$212
75 mg
$306
100 mg
$POA
Quantity
1
Total amount
$ 80
ICI 182,780 | faslodex | fulvestrant
No data available
The compound has purity validated by NMR and/or LCMS methods.
Target activity features
It should be emphasized that the product may be active against a larger number of targets than shown on the card. The information represented here refers to the targets with the largest value of pX or the targets with ΔpX less than 1.5 from the largest pX value.